Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
주식 순위 #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
주가
$0.1559364
마지막 동기화: 2026-09-18
시가총액
$195.17K
변동 (1일)
6.60%
변동 (1년)
-30.91%
국가
GB
거래 Fusion Antibodies plc (FAB)

카테고리

Fusion Antibodies plc (FAB)의 매출
Sep 2025 기준 매출 TTM: $2.15M
Fusion Antibodies plc의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $2.15M입니다. 2024년에 회사는 $1.43M의 수익을 올렸으며 이는 2023년의 $3.58M 대비 감소입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Fusion Antibodies plc의 수익 기록 (2013 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) $2.15M -15.49%
2025 $2.54M 77.00%
2024 $1.43M -59.95%
2023 $3.58M -43.24%
2022 $6.31M 9.89%
2021 $5.74M 18.80%
2020 $4.83M 70.09%
2019 $2.84M -24.66%
2018 $3.77M 57.07%
2017 $2.40M 12.81%
2016 $2.13M 57.86%
2015 $1.35M 11.90%
2014 $1.20M 95.78%
2013 $615.46K 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B 588,305.51%
US
$6.02B 280,545.95%
NL
$2.23B 103,744.77%
US
$15.74B 733,726.73%
AU
- -
CH